Podcast summary
TWiP 279: Tolling for hookworms
TLR4 adjuvant drives early hookworm protection
A phase II trial of NAGST1 hookworm vaccine on L-hydrogel tested three adjuvant strategies in naïve adults using controlled infection. Only NAGST1+CPG (TLR9 agonist) sharply reduced tissue-stage migration and egg output, selecting it for further study.
Eosinophils imply the vaccine blocks migration
Lower eosinophil peaks in NAGST1+CPG suggest the immune response curtails the early tissue invasion stage, before intestine establishment and egg production; the near-zero fecal egg counts then match that mechanism.
Field efficacy may fail without post-infection window
Because helminths often induce immune tolerance and natural infections don’t generate durable protective immunity, performance in already-infected, endemic populations may drop; a likely next design is treating first, then vaccinating.
Get smarter in 10 seconds
Koficast is a free newsletter delivering clear, high-signal takeaways like these from the best podcasts, picked for you.
Zero spam. Emails auto-pause if you’re not opening.